Cap On Mini-Sentinel Funds Raised To $135 Mil. To Support Powerful Surveillance Resource
This article was originally published in The Gray Sheet
Executive Summary
Funds for FDA’s Mini-Sentinel post-market surveillance program were originally capped at $100 million based on projections for a consortium of at least three automated health care data partners to build analysis capabilities for data covering 100 million patients. The project has significantly exceeded those goals.
You may also be interested in...
FDA Reconsiders UDI Direct Marking Requirements For Implants
An agency official says FDA is reworking the UDI direct part marking requirements for implants and making other changes in the final unique device identification rule, due out in June.
Mini-Sentinel Expanding Drug Safety Efforts To Prospective Surveillance
The effort will complement the FDA-funded project’s existing ability to retrospectively measure exposure to products and then analyze specific adverse outcomes.
Mini Sentinel Alleviates FDA Concern Over Pradaxa Bleeding Issue
Data from the pilot program a “driving factor” in the agency’s decision against changing its recommendations for the blood thinner following reports of increased serious bleeding events.